INM005

Inmunova S.A. · Phase 2 active Small molecule

At a glance

Generic name	INM005
Sponsor	Inmunova S.A.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study
A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19. (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INM005 CI brief — competitive landscape report
INM005 updates RSS · CI watch RSS
Inmunova S.A. portfolio CI